The Scottish Medicines Consortium has recommended olaparib to treat NHS patients with advanced breast cancer – ICR
The Institute of Cancer Research (ICR) shared a post on LinkedIn:
“We’re delighted that The Scottish Medicines Consortium (SMC) has today recommended that olaparib (also known as Lynparza) can be used to treat NHS patients in Scotland with advanced breast cancer.
The treatment offers the chance of longer, healthier lives for people with breast cancer caused by faulty BRCA1 or BRCA2 genes.
The ICR has played a crucial role in the development of targeted PARP inhibitor drugs like olaparib, dating back to our discovery of the BRCA2 gene in 1995.
Following that discovery, researchers in the Breast Cancer Now, Toby Robins, Research Centre at the ICR carried out early laboratory work which revealed how PARP inhibitors could target cancers with mutations in BRCA1 and BRCA2.
Earlier this year, a similar decision was made by NICE regarding access to olaparib on the NHS in England. At the time, our Chief Executive, Professor Kristian Helin, said:
‘I’m proud of the decades of research at the ICR that have underpinned this achievement.’
More posts featuring The Institute of Cancer Research.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023